Characterization and phase I study of CLR457, an orally bioavailable pan-class I PI3-kinase inhibitor

Background CLR457 is an orally bioavailable pan-phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) inhibitor. Methods CLR457 anti-tumor activity and pharmacokinetics (PK) were characterized by in vitro biochemical assays and in vivo tumor xenografts. A first-in-human study was conducted to determ...

Descripción completa

Detalles Bibliográficos
Autores principales: Harding, James J., Bauer, Todd M., Tan, Daniel S. W., Bedard, Philippe L., Rodon, Jordi, Doi, Toshihiko, Schnell, Christian, Iyer, Varsha, Baffert, Fabienne, Radhakrishnan, Rajkumar, Fabre, Claire, Juric, Dejan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2018
Materias:
Phase I Studies
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6440935/
https://www.ncbi.nlm.nih.gov/pubmed/30073466
http://dx.doi.org/10.1007/s10637-018-0627-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6440935/
https://www.ncbi.nlm.nih.gov/pubmed/30073466
http://dx.doi.org/10.1007/s10637-018-0627-4

Ejemplares similares